Clinical Trial

The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

Study acronym: MORNING-RWS
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 15, 2025 (before its estimated December 17, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an observational study. All patients who meet the inclusion criteria of our previous Phase 2, open-label, single-arm study of neoadjuvant immune-checkpoint blockade therapy (AK104) combining with TACE for resectable hepatocellular carcinoma, but refuse to receive neoadjuvant treatment will be asked again to participate this observational study retrospectively and prospectively. Participants will receive surgery and regular monitoring for 1 year. The purpose is to provide real-world cohort for comparison with the neoadjuvant cohort.
Trial Details
NCT Number NCT07064681
Lead Sponsor Sun Yat-sen University
Conditions Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Enrollment 100 participants
Start Date 2025-07-05
Primary Completion 2025-12-17 (estimated)
Study Completion 2026-12-17 (estimated)
Updated on ClinicalTrials.gov 2025-07-15